# HELLP Syndrome

HELLP syndrome requires rapid confirmation of microangiopathic hemolysis, hepatic injury, and thrombocytopenia; stabilization of severe hypertension and seizure risk; exclusion of competing thrombotic microangiopathies and acute fatty liver; and delivery when maternal or fetal status warrants.

**Clinical question:** How should clinicians confirm, stabilize, differentiate, and manage suspected HELLP syndrome during pregnancy or the first postpartum week?

Updated: 2026-08-24T17:58:29.842922+00:00

## What matters in practice
- Confirm HELLP with hemolysis plus platelet count below 100,000/μL and AST or ALT more than twice the upper limit of normal; LDH greater than 600 IU/L and bilirubin above 1.2 mg/dL support the diagnosis. [2][12][14]
- Treat HELLP as an obstetric emergency: severe hypertension, neurologic symptoms, pulmonary edema, renal dysfunction, severe epigastric pain, eclampsia, or fetal compromise are indications to expedite delivery rather than expectant management. [1][6]
- Do not attribute every pregnancy-associated thrombotic microangiopathy to HELLP; TTP can closely mimic HELLP and requires a distinct hematologic treatment pathway. [2][5]
- Disease can first present postpartum, usually within the first week; continue blood pressure, platelet, hemolysis, and hepatic laboratory surveillance after delivery. [3][9][11]
- Magnesium sulfate is recommended for seizure prophylaxis in preeclampsia with severe features during labor and delivery and for 24 hours postpartum; severe hypertension requires pharmacologic treatment. [6][15]

## Recognize HELLP and identify patients requiring urgent delivery

Triage simultaneously for maternal end-organ injury, hemorrhagic complications, and fetal compromise.

Suspect HELLP in a patient at 28 to 36 weeks' gestation or within 7 days postpartum who has right-upper-quadrant or epigastric pain, nausea or vomiting, headache, malaise, hypertension, proteinuria, or otherwise unexplained thrombocytopenia and transaminitis. Hypertension and proteinuria occur in up to 85% of cases, so their absence does not exclude HELLP. [3][9][11]

Escalate immediately to obstetrics/MFM and a delivery-capable setting when there is eclampsia, severe hypertension, severe epigastric pain, pulmonary edema, worsening renal dysfunction, major maternal organ morbidity, or nonreassuring fetal status. These findings favor delivery over continued observation because HELLP is a severe hypertensive disorder with risk of progression and maternal morbidity. [1][6]

Evaluate acute right-upper-quadrant pain with particular urgency when accompanied by hemodynamic instability, falling hemoglobin, or rapidly worsening liver tests, because HELLP may be complicated by hepatic hematoma, infarction, or rupture. Placental abruption should be considered with abdominal pain and a firm, painful uterus; abruption occurs in up to 10% of preeclamptic pregnancies. [2][7]
- Obtain continuous or frequent maternal blood pressure assessment and fetal assessment while diagnostic laboratories are pending. [6]
- Assess for neurologic symptoms, visual changes, dyspnea or hypoxemia, pulmonary edema, severe abdominal pain, vaginal bleeding, and uterine tenderness at presentation and with every clinical deterioration. [6][11]
- Treat new generalized tonic-clonic seizure in this setting as eclampsia while evaluating alternative neurologic causes. [10][12]

*Features that should move suspected HELLP from evaluation to expedited delivery planning. [1][6]*

| Finding | Clinical implication | Next action |
| --- | --- | --- |
| Eclampsia or major neurologic morbidity | Maternal neurologic emergency. [1][6] | Initiate magnesium sulfate and expedite delivery after maternal stabilization. [6] |
| Severe hypertension | High stroke risk; central nervous system hemorrhage is a major cause of death in HELLP syndrome. [1] | Administer antihypertensive therapy and proceed with delivery planning. [1][6] |
| Severe epigastric pain or major organ-system morbidity | Signals severe disease and possible hepatic complication. [1][7] | Urgent maternal assessment, evaluate hepatic complication when clinically indicated, and expedite delivery. [1] |
| Pulmonary edema, worsening renal dysfunction, or fetal distress | Maternal or fetal deterioration is an indication for earlier delivery. [6] | Stabilize the specific complication and deliver when feasible. [6] |

## Confirm the HELLP laboratory pattern and establish severity

Order hemolysis, platelet, hepatic, renal, and coagulation studies together; trends matter when disease is evolving.

Obtain CBC with platelet count, peripheral blood smear, AST, ALT, total and indirect bilirubin, LDH, serum creatinine, and urine protein assessment in any patient with suspected HELLP. Confirm microangiopathic hemolysis with schistocytes or burr cells on smear and supportive evidence such as LDH greater than 600 IU/L, indirect hyperbilirubinemia, or low haptoglobin. [2][11][14]

Use the full triad for a firm diagnosis: platelet count below 100,000/μL, AST or ALT greater than twice the upper limit of normal, and hemolysis. Commonly used supporting thresholds include AST at least 70 IU/L, LDH above 600 IU/L, and total bilirubin above 1.2 mg/dL. Differences among Mississippi, Tennessee, and ACOG-derived criteria mean that a patient with evolving or partial disease warrants serial reassessment rather than exclusion solely because one threshold is not met. [2][12][14]

Classify thrombocytopenia to communicate severity and anticipate hemorrhagic risk: Mississippi class I is platelet count below 50,000/μL, class II is 50,000 to 100,000/μL, and class III is 100,000 to 150,000/μL with hemolysis and elevated liver enzymes. Partial HELLP may progress to complete disease, particularly when severe hypertension, eclampsia, severe epigastric pain, or organ morbidity is present. [1][14]

Add coagulation testing when bleeding, abruption, hepatic injury, or severe systemic illness is present. Disseminated intravascular coagulation is a recognized HELLP complication and may manifest with elevated fibrin degradation products. [3]
- Repeat platelet count, AST/ALT, LDH, bilirubin, creatinine, and clinical assessment when symptoms worsen or results are borderline, because HELLP may evolve rapidly. [1][3]
- Interpret an elevated creatinine, platelet count below 100,000/μL, liver enzymes above 80 IU/L, severe hypertension, severe headache, visual symptoms, dyspnea, or epigastric pain as severe-feature findings in the hypertensive-disorder framework. [10]
- Do not require proteinuria to evaluate for HELLP; a meaningful minority of affected patients lack hypertension or proteinuria. [3][9]

*Laboratory thresholds used to support HELLP syndrome diagnosis and severity classification. [2][12][14]*

| Domain | Threshold or finding | Interpretation |
| --- | --- | --- |
| Hemolysis | LDH >600 IU/L; abnormal smear with schistocytes or burr cells; bilirubin >1.2 mg/dL supports hemolysis. [2][14] | Establishes the H component when integrated with clinical and other laboratory data. [2][14] |
| Liver injury | AST or ALT >2× upper limit of normal; AST ≥70 IU/L is used in Mississippi and Tennessee criteria. [12][14] | Establishes the EL component. [12][14] |
| Thrombocytopenia | Platelets <100,000/μL. [2][12][14] | Establishes the LP component and is a severe-feature threshold. [10] |
| Mississippi class I | Platelets <50,000/μL. [14] | Most severe platelet-based class. [14] |
| Mississippi class II | Platelets 50,000–100,000/μL. [14] | Complete HELLP platelet range when other criteria are present. [14] |
| Mississippi class III | Platelets 100,000–150,000/μL with hemolysis and elevated liver enzymes. [14] | Partial or less severe platelet-based category requiring close reassessment. [14] |

## Separate HELLP from competing pregnancy-associated microangiopathies and liver disease

The most consequential diagnostic error is missing TTP or acute fatty liver of pregnancy while assuming all abnormalities are HELLP.

TTP can have the same core findings as HELLP: thrombocytopenia, microangiopathic hemolytic anemia, renal disease, and neurologic abnormalities. In preeclampsia-associated HELLP, hypertension, proteinuria, and edema tend to precede hematologic abnormalities; in TTP, hypertension and proteinuria may follow hematologic disease. When thrombocytopenia and hemolysis are disproportionate to hepatic injury, or neurologic and renal findings dominate, involve hematology urgently and evaluate for TTP rather than relying on delivery as the sole intervention. [2][5]

Acute fatty liver of pregnancy is a key competing diagnosis in late pregnancy because it may overlap with HELLP in nausea, vomiting, liver dysfunction, thrombocytopenia, and systemic illness. Evaluate glucose, renal function, bilirubin, and coagulation status alongside HELLP laboratories when acute liver failure physiology or coagulopathy is present; AFLP and HELLP have similar clinical and laboratory presentations and require deliberate distinction. [5][21]

Consider antiphospholipid syndrome and hemolytic uremic syndrome in pregnancy-associated thrombotic microangiopathy, particularly when the timing, renal injury, thrombotic history, or laboratory pattern is atypical for hypertensive disease. These entities are specifically recognized in the differential diagnosis of HELLP. [5]

Do not label isolated pruritus and cholestatic liver-test elevation as HELLP without evidence of hemolysis and thrombocytopenia. Intrahepatic cholestasis of pregnancy is a diagnosis of exclusion, and ursodeoxycholic acid is first-line therapy at 10 to 15 mg/kg maternal body weight when ICP is diagnosed. [9]
- Favor HELLP when hemolysis, elevated transaminases, and platelet count below 100,000/μL occur with a hypertensive-disorder phenotype, but continue reassessment if the trajectory is atypical. [2][12]
- Escalate suspected TTP to hematology urgently because it shares the HELLP laboratory phenotype but has a separate treatment pathway. [2][5]
- Obtain targeted imaging for suspected hepatic hematoma, infarction, or rupture when severe right-upper-quadrant pain is accompanied by instability or evidence of bleeding. [7][20]

*High-stakes differential diagnosis of thrombocytopenia, hemolysis, and liver abnormalities in pregnancy. [2][5][9][21]*

| Condition | Pattern that changes the differential | Action |
| --- | --- | --- |
| HELLP syndrome | Hemolysis, platelet count <100,000/μL, and transaminase elevation; hypertension and proteinuria are common but not universal. [2][9][12] | Stabilize severe features, begin seizure prophylaxis when indicated, and plan delivery based on maternal-fetal status. [6] |
| Thrombotic thrombocytopenic purpura | May be indistinguishable by thrombocytopenia, hemolytic anemia, renal disease, and neurologic abnormalities; hypertension/proteinuria may follow hematologic findings. [2] | Urgent hematology involvement and TTP-directed evaluation; do not assume delivery alone addresses the process. [2][5] |
| Acute fatty liver of pregnancy | Overlaps with HELLP; assess for acute liver failure physiology, hypoglycemia, renal dysfunction, and coagulopathy. [5][21] | Urgent obstetric and critical-care assessment with delivery planning and management of hepatic failure complications. [21] |
| Hemolytic uremic syndrome or antiphospholipid syndrome | Pregnancy-associated thrombotic microangiopathy or thrombotic phenotype atypical for HELLP. [5] | Obtain specialist-directed evaluation and treat the identified disorder rather than applying a HELLP-only pathway. [5] |
| Intrahepatic cholestasis of pregnancy | Cholestatic liver disease without the defining HELLP hemolysis-thrombocytopenia pattern. [9] | Exclude other causes; use ursodeoxycholic acid 10–15 mg/kg when ICP is diagnosed. [9] |

## Stabilize severe features while preparing definitive obstetric management

Delivery is definitive treatment for the hypertensive disorder; stabilization prevents stroke, seizure, and cardiopulmonary deterioration during that process.

Manage HELLP as preeclampsia with severe features: stabilize blood pressure, prevent eclampsia, assess volume status and pulmonary edema, correct clinically significant hemorrhagic complications, and coordinate anesthesia, obstetric, neonatal, and critical-care planning according to maternal and fetal condition. Definitive treatment of preeclampsia-spectrum disease is delivery. [6][12][13]

Administer magnesium sulfate for seizure prophylaxis in women with preeclampsia with severe features during labor and delivery and continue for 24 hours postpartum. Use this pathway in HELLP because HELLP is managed as a severe preeclampsia phenotype and eclampsia can occur intrapartum or postpartum. [6][12][15]

Treat severe hypertension pharmacologically without delay; intensive antihypertensive treatment is used to minimize severe systolic hypertension and its associated stroke risk in HELLP. Select the agent based on clinician experience, cost, and local availability; the cited guideline comparison does not establish a single preferred medication or dose. [1][6]

Do not use corticosteroids as maternal disease-directed treatment for HELLP outside an individualized specialist plan. Guideline comparison data specifically advise against corticosteroids for treating HELLP, despite older literature describing possible maternal-fetal benefit; this disagreement does not alter the need for maternal stabilization and delivery when indicated. [6][7]
- Use delivery planning immediately for HELLP with uncontrolled severe-range blood pressure, persistent headache or upper abdominal pain, visual symptoms, stroke, myocardial infarction, worsening renal function, pulmonary edema, eclampsia, or abnormal fetal testing. [6]
- Involve anesthesia early when thrombocytopenia is substantial or hemorrhage and urgent operative delivery are plausible; platelet trajectory and coagulation status should inform procedural planning. [3][14]
- Monitor for pulmonary edema and avoid uncritical volume loading; volume status is a recognized component of acute supportive management. [11]

### Delivery timing and expectant management

HELLP syndrome itself is an earlier-delivery indication in guideline comparisons of hypertensive disorders of pregnancy. Continued observation may be considered only when maternal and fetal status are stable in a setting capable of serial maternal laboratory testing, blood-pressure treatment, fetal surveillance, and immediate delivery; instability overrides gestational-age considerations. [6][13]

At any gestational age, class III or partial HELLP accompanied by eclampsia, severe epigastric pain, severe hypertension, or major organ-system morbidity should be treated as severe disease requiring escalation and delivery planning. [1]

*Immediate management priorities in HELLP syndrome. [1][6][11][12][13]*

| Priority | Specific action | Monitoring endpoint |
| --- | --- | --- |
| Seizure prevention | Magnesium sulfate during labor and delivery and for 24 hours postpartum in preeclampsia with severe features. [6] | Recurrent seizure, respiratory status, and clinical toxicity surveillance. [11][12] |
| Severe hypertension | Administer antihypertensive therapy for severe hypertension. [1][6] | Avoid persistent severe systolic hypertension because of stroke risk. [1] |
| Pulmonary edema or volume concern | Assess volume status and manage pulmonary edema as an acute complication. [11] | Oxygenation, respiratory effort, fluid balance, and blood pressure. [11] |
| Definitive treatment | Expedite delivery for HELLP with maternal or fetal deterioration. [6][13] | Maternal stabilization and fetal assessment through delivery. [6] |

## Continue surveillance postpartum and reconsider the diagnosis if recovery is atypical

Delivery ends the pregnancy trigger but does not eliminate immediate postpartum risk.

Continue inpatient clinical and laboratory surveillance after delivery because HELLP can develop during the first postpartum week and eclampsia most often occurs from intrapartum through 72 hours postpartum. Follow blood pressure, symptoms, platelet count, hemolysis markers, liver tests, renal function, respiratory status, and bleeding risk until the trajectory is clearly improving. [3][9][12]

Continue magnesium sulfate for 24 hours postpartum when the patient meets the severe-feature prophylaxis pathway. Treat postpartum severe hypertension pharmacologically; international guideline comparisons endorse treatment of severe hypertension during pregnancy and postpartum. [6]

If platelet count, hemolysis, renal injury, neurologic dysfunction, or hepatic abnormalities fail to improve as expected after delivery, reopen the differential rather than assuming persistent HELLP. TTP, hemolytic uremic syndrome, antiphospholipid syndrome, and acute fatty liver of pregnancy are competing diagnoses that require disease-specific evaluation and management. [2][5][21]

Arrange postpartum support and counseling after a severe hypertensive pregnancy complication; affected patients and families may have substantial psychological distress, and postpartum management should include psychological and family support. [6]
- Reassess urgently for headache, visual symptoms, seizure, dyspnea, severe hypertension, recurrent epigastric pain, bleeding, or reduced urine output after delivery. [6][11][12]
- Do not discontinue diagnostic vigilance solely because delivery has occurred; postpartum-onset HELLP remains possible for up to 7 days. [9][11]
- Escalate persistent thrombotic microangiopathy features to hematology and nephrology as clinically indicated. [2][5]

*Postpartum monitoring decisions after HELLP syndrome. [3][6][9][12]*

| Postpartum finding | Interpretation | Next step |
| --- | --- | --- |
| New or persistent severe hypertension | Ongoing severe hypertensive disease and stroke risk. [1][6] | Administer antihypertensive therapy and reassess for neurologic and cardiopulmonary complications. [6] |
| Seizure within 72 hours postpartum | Compatible with eclampsia in the preeclampsia spectrum. [12] | Treat as eclampsia and continue severe-feature evaluation. [6][12] |
| Persistent thrombocytopenia, hemolysis, renal injury, or neurologic dysfunction | May indicate TTP, HUS, or another thrombotic microangiopathy rather than resolving HELLP. [2][5] | Urgent specialist-directed evaluation for an alternate diagnosis. [2][5] |
| HELLP-like symptoms or laboratory abnormalities within 7 days postpartum | Postpartum HELLP remains possible. [9][11] | Repeat HELLP laboratory evaluation and manage as a hypertensive obstetric emergency when criteria or severe features are present. [11][12] |

## References
1. HELLP syndrome - Management Approach | BMJ Best Practice — bestpractice.bmj.com — https://bestpractice.bmj.com/topics/en-gb/1000/management-approach
2. Eclampsia and Preeclampsia - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/eclampsia-and-preeclampsia
3. The interpretation of liver function tests in pregnancy — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1521691820300020
4. Clinical diagnosis and treatment of “atypical” HELLP ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2667164622000677
5. HELLP Syndrome Developing at 14 Weeks of Gestation — www.sciencedirect.com — https://www.sciencedirect.com/org/science/article/pii/S1573404823000018
6. Prevention, Diagnosis and Management of Hypertensive Disorders of Pregnancy: A Comparison of International Guidelines - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC7773049
7. Understanding and managing HELLP syndrome: The integral role of aggressive glucocorticoids for mother and child - American Journal of Obstetrics & Gynecology — www.ajog.org — https://www.ajog.org/article/S0002-9378(05)01367-0/fulltext
8. The HELLP syndrome: Clinical issues and management. A Review — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC2654858
9. Managing hepatic complications of pregnancy: practical strategies for clinicians - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8928321
10. ACOG and local diagnostic criteria for hypertensive disorders of pregnancy (HDP) in La Paz-El Alto, Bolivia: A retrospective case-control study — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9205446
11. HELLP Syndrome - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK560615
12. Hypertension In Pregnancy - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK430839
13. Preeclampsia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK570611
14. Clinical Reasoning: A 32-Year-Old Woman Presenting With Thunderclap Headache in the Third Trimester — www.neurology.org — https://www.neurology.org/doi/10.1212/WNL.0000000000214029
15. Plasma exchange in severe postpartum HELLP syndrome — pubmed.ncbi.nlm.nih.gov — https://pubmed.ncbi.nlm.nih.gov/12190795
16. Table B-1, Excluded articles and records with reasons for exclusion - Management of Postpartum Hypertensive Disorders of Pregnancy - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK592556/table/appb.tab1
17. Preeclampsia: Pathophysiology, Management, and ... — publications.aap.org — https://publications.aap.org/neoreviews/article/14/1/e4/89405/Preeclampsia-Pathophysiology-Management-and
18. Revisiting HELLP syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0009898115300267
19. HELLP Syndrome - an overview — www.sciencedirect.com — https://www.sciencedirect.com/topics/medicine-and-dentistry/hellp-syndrome
20. Extensive hepatic infarction in severe preeclampsia as part ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1028455912001325
21. Review Imaging of pregnancy-related liver diseases — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S2772947823000099
22. A life-saving therapy in Class I HELLP syndrome — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S147305021400264X
23. Direct evidence of complement activation in HELLP ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S0301472X16000345
24. Does the hepatologist still need to rely on ... — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1665268125001243

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.